News
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. ("Sinopharm Xingsha") to conduct cross-border sales of Tru Niagen® in mainland China. Sinopharm Xingsha is a subsidiary of...
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
New preclinical data from the ChromaDex External Research Program (CERP) shows positive effects of nicotinamide riboside (NR) in glaucoma, Alzheimer's disease, and cardiac ischemia-reperfusion injury mouse models LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today...
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc. ("Elysium")...
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
Tru Niagen® net sales of $15.4 million for the three months ended June 30, 2021, up 31% from the prior year quarter, with total company net sales of $17.7 million and gross margin of 61.1% for the quarter. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today...
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. The financial results will be reported in a press release...
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)
New preclinical research in mice finds nicotinamide riboside (NR) prevented loss of bone mass, reduced neuroinflammation, and reduced the negative effects of alcohol-induced inflammation LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four...
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
Walmart partnership brings industry-leading NAD+ booster and healthy aging nutrient Tru Niagen® to major U.S. retail stores for the first time LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of its flagship consumer product Tru Niagen®...
ChromaDex Corporation Reports First Quarter 2021 Financial Results
Tru Niagen® Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of 62.9%. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021...
ChromaDex and Ro Partner for New Product Development
ChromaDex and healthcare technology company Ro announce supply agreement for Niagen® LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The...
ChromaDex to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET (8:30am PT). ChromaDex CEO, Rob Fried, will also be presenting on a panel in the...